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Summary: An immunofluorometric sandwich assay for determination of S-100 protein in cerebrospinal fluid (CSF)
and blood is described. The lower detection limit was 0.015 μ§/1 of S-100 protein. Intra-assay and inter-assay
imprecision (coefficients of variation, CVs) were 2.1 to 3.2% and 7.8 to 11.6%, respectively. S-100 protein recovery
in cerebrospinal fluid was 94 to 103%. In blood the recovery varied from 67 to 96%, depending on blood samples
used and the concentration of S-100 protein. The best recovery in blood was found using heparinized plasma. In
healthy subjects 0.098 ±0.11 μg/l (mean ± SD) of S-100 protein was detected (n = 30). In the CSF of otherwise
healthy patients undergoing a myelography for lumbar pain 1.43 ± 0.49 μg/l (mean ± SD) of S-100 protein was
found. Preliminary results from longitudinal studies on S-100 protein in neurosurgical patients indicate a positive
correlation between S-100 protein blood levels and clinical course. Thus, the determination of S-100 protein in
blood appears to be helpful in the monitoring of patients with neuronal damage.
Introduction
Every physician involved in the care of neurologically
diseased patients in intensive care medicine faces the
problem of evaluating patients in coma or under general
anaesthesia. In many of these cases, classical neurologi-
cal examination alone does not allow sufficient monitor-
ing on the intensive care unit for therapeutic guidance or
allow early diagnosis of complications. Even computed
tomography (CT) and nuclear magnetic resonance
(NMR) imaging are not always able to differentiate oe-
dema from structurally damaged neuronal tissue. This is
especially true in the acute phase of brain damage. In
addition, neuroradiological techniques are expensive and
require transportation, which is not without risk for criti-
cally ill patients. Monitoring of intracranial pressure,
electroencephalogram (EEG) or sensory evoked re-
sponse are valuable tools and can provide important in-
formation but do not prove neuronal destruction. In ad-
dition, in intensive care units these methods may be sus-
ceptible to technical interference. There is evidence,
however, that cerebrospinal fluid markers such as S-100
protein, glial fibrillary acidic protein, neuron-specific
enolase and myelin basic protein may serve as quantita-
tive markers of the extent of brain damage.
The term "S-100" refers to a mixture of dimeric proteins
consisting of two subunits of Mr 10500 termed α and β
(1). Three isoforms are known. S-100a (αβ) is found in
glial cells and melanocytes. S-100b (ββ) is present in
high concentration in glial cells and Schwann cells of
the central and peripheral nervous system as well as in
Langerhans cells and cells of the anterior pituitary. S-
100ao (αα) which represents 5% of the S-100 protein
population in brain is found outside the nervous system
in slow-twitch muscle, heart and kidney (2). The S-100
protein family constitutes a subgroup of Ca2+-binding
proteins of the EF-hand type (3). Apart from calcium
they can also bind zinc. Both intracellular and extracel-
lular mechanisms of action have been proposed for S-
100 protein, although its biological functions are not yet
understood in detail (3). S-100 protein is stable in CSF
for 2 days at 4 °C (4).
Several studies on patients with neurological lesions
have shown a relationship between cell damage in the
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central nervous system and the'concentration of S-100
protein in cerebrospinal fluid (CSF) (5-13). However,
especially in patients with substantial lesions of the
brain (large tumour, infarction, intracerebral or sub-
arachnoid haemorrhage, neurotrauma) intracrani l pres-
sure may be increased and lumbar puncture is contrain-
dicated due to the risk of transtentorial herniation. CSF
can be obtained by cannulation of the lateral ventricles.
This is, however, not without risk and during cannula-
tion nervous tissue will be damaged, which may distort
measurements (14, 15).
For these reasons, substances which are released from
brain cells during brain damage must be detectable in
blood if they are to serve as a useful tool in clinical
medicine. In contrast to CSF, however, studies on S-100
protein levels in blood are rare (9). A correlation be-
tween S-100 protein levels in blood and damage of the
nervous system has not previously been reported. We
describe a method for quantifying S-100 protein concen-
trations in blood and CSF and report the first clinical
results obtained with the assay under routine conditions.
Materials and Methods
Samples
Reference population
CSF was obtained from 53 patients (25 male, 28 female) aged 17—
76 years (55.2 ± 14.2, mean ± SD) who underwent myelography
for lumbar pain. Medical history and neurological evaluation re-
vealed no evidence for organic nervous disease. Total protein con-
centration and cell count in CSF specimens were both normal. Se-
rum and heparinized plasma samples (ammonium heparin, 15
X 103 1U/1) were obtained from 30 healthy subjects (15 male, 15
female) aged 21-52 years (32.5 ± 7.7, mean ± SD).
Neuroswgical patients
Heparinized plasma and, if available, CSF samples from lumbar
punctures, lumbar catheters and lateral ventricle cannulations were
obtained for routine analysis from patients of the neurosurgical in-
tensive care unit of the Medical University of L beck.
CSF samples from lateral ventricle cannulation of four patients
were selected for dilution and analytical recovery experiments.
Eleven serum and heparinized plasma samples of healthy subjects
were selected for the calcium dependency experiments, and a fur-
ther 12 samples for dilution studies. All dilutions were made in
horse serum (Gibco, Eggenstein, Germany). All blood CSF sam-
ples were centrifuged within three hours and the supernatant stored
in aliquots of 500 μΐ at -70 °C.
Materials
All chemicals were obtained from Merck (Darmstadt, Germany)
unless stated otherwise. Purified S-100a, S-100b and S-100ao pro-
teins from Sigma (Deisenhofen, Germany) were used for S-100
protein subtype cross-reactivity experiments and as calibrator.
Antibodies
The polyclonal antibody was raised in rabbit with bovine brain S-
100 protein purified by the method of Moore (1) as antigen
(DAKO, Hamburg, Germany). After plasma adsorption the speci-
fity of the antibody was proven by immunoelectrophoresis and en-
zyme immunoassay. The antibody was labelled with biotin as de-
scribed previously (16).
Assay procedure ,
 f
Microtitre plates (Nunc Maxisorp, Roskilde, Denmark) were coated
with anti-Si00 protein antibody (DAKO) 900 ng/well in 200 μΐ
phosphate buffer, 0.05 mol/1, pH 8.6 and allowed to stand overnight
at 4 °C. After washing the plates twice with 5 ml/well of washing
buffer (Tris 0.05 mol/1, NaCl 0.15 mol/1, Tween 20 0.1 ml/l, pH
7.5) using a Novopath Platewasher (Bio Rad, M nchen, Germany)
they were postcoated for 15 minutes with 300 μΐ of carbonate
buffer 0.05 mol/1, pH 9.6 containing bovine serum albumin 10 g/1
(Sigma) and washed again once with washing buffer. The plates
were either used fresh, or were stored at 4 °C with 200 μΐ coating
buffer per well and sealed with microtitre plate sealings (ICN,
Eschwege, Germany). The plates could be stored in this way for
12 weeks without loss in immunoreactivity.
All measurements were set up in duplicate at room temperature.
Incubations were performed on a microtitre plate shaker (Heidolph,
Kehlheim, Germany) at 200 min"1. CSF samples were measured
undiluted and after 1 : 100 dilution in horse serum. S-100 protein
calibrators, controls, samples (200 μΐ) and 50 μΐ of horse serum
(Gibco) with CaCl2 25 mmol/1 were added to each well and incu^·
bated for 2 hours. Purified S-lOO^ (1 + 1, by vol.) in horse serum
was used for calibrators and controls. The plates were washed with
washing buffer three times, and 200 μΐ of biotin-labelled anti S-
100 protein antibody diluted to a final concentration of 2 μ^ in a
Tris 0.05 mol/1, NaCl 0.15 mol/1, CaCl2 10 mmol/1, NaN3 0.15
mmol/1 buffer containing horse serum, volume fraction 0.5, was
added and incubated for one hour.
The plates were again washed three times with washing buffer,
after which 200 μΐ of streptavidin-europium were added to each
well and incubated for 30 minutes. Streptavidin was labelled as
recommended by Pharmacia (Uppsala, Sweden) using their euro-
pium-labelling-reagent, and then diluted to a final concentration of
0.025 mg/1 in Tris 0.05 mol/1, NaCl 0.15 mol/1, NaN3 0.15 mmol/1,
diethylenetriaminopentaacetic acid 0.02 mmol/1, bovine serum al-
bumin 5 g/1 and bovine γ-globulin 0.5 g/1 (Sigma), pH 7.5. The
plates were washed again three times with washing buffer. En-
hancement solution (200 μΐ/well; acetic acid 0.01 mol/1, tri-n-octyl
phosphine oxide 38 mg/1, potassium phthalate 1.3 g/1, thenoyltriflu-
oroacetone 222 mg/1, Triton X-100 2 mol/1) was incubated for 15
minutes. The resulting fluorescence was measured in the DELF1A
1232 fluorometer (Pharmacia). The calibration curve was con-
structed using a modified spline function in the FIA-Calc data re-
duction program of the DELF1A 1232 system after a log/log trans-
formation of the data.
Effect of calcium concentration on the S-100 protein
assay
To evaluate the effect of calcium concentration on the S-100 pro-
tein assay we obtained serum and heparinized plasma samples from
11 healthy subjects. S-100^ (1 + 1, by vol.) and CaCl2 was added
to give final concentrations of 1 and 10 μg/l of S-100 protein and
2, 5, 10 and 20 mmol/1 of CaCl2, respectively. For this experiment
the buffer solutions described above did not contain calcium.
Results
Assay characteristics
A typical calibration curve of the S-100 protein assay is
shown in figure L The lower detection limit was 0.015
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μg/l (Ο + 3 SD, n = 24) of S-100 protein. The calibra-
tion curve ranged from 0.02 to 25 pg/l. A high dose
"hook"-effect did not occur even at S-100 protein con-
centrations of 10000 μg/l (fluorescence reading for cali-
brator 25 μ^: 1419080 s"1, 10000 μg/l: 2483335
s""1). Coated microtitre plates stored in buffer for 3
months at 4 °C gave the same results as freshly prepared
plates. The lower detection limit of the assay depended
on the calcium concentration (tab. 1). With increasing
CaCl2 concentrations up to 10 mmol/1, the measured S-
100 levels in serum and heparinized plasma of healthy
volunteers also steadily increased. Since the best analyti-
cal recovery after addition of S-100 protein to blood was
achieved with 5 mmol/1 of CaCl2, this calcium concen-
tration was chosen for assay buffers. S-100 protein in
heparinized plasma was stable for 24 hours at 20 °C
(10% loss), for four days at 4 °C (without loss) and for
at least 6 months at —20 °C. Even four cycles of freez-
ing and thawing did not affect S-100 levels in plasma
(data not shown).
Precision
The intra-assay (within-run) imprecision (CVs) was
3.2% at 0.51 μg/l, 2.1% at 5.97 μ^Ι, and 2.3% at 11.4
μg/l (n = 20). The total imprecision (between-day, CVs)
was 11.5% at 0.45 μ§/1, 7.9% at 4.79 μg/l, and 7.8% at
15.45 μg/l (n = 21).
S-100 subtype cross reactivity
The assay detected predominantly S-100b. Cross reac-
tion by S-100
 ao was less than 1% (tab. 2).
Recovery experiments
The recovery after mixing different CSF samples varied
from 94% to 103% (tab. 3). Serial dilution experiments
proved the linearity of the assay (figs. 2 and 3). The
results were different for serum and heparinized
plasma (tab. 4).
10000-1
1000-
100-
10-
0.01 0.1 1 10 100
Protein S-100 [μο/Ι]
Fig. 1 Typical calibration curve of the S-100 protein assay.
Tab. 1 S-100 protein concentrations in serum and heparinized
plasma of 11 healthy subjects after addition of calcium and S-100
protein.
Calcium added
[mmol/li
Serum (n = 11)
-
2
5
10
Heparinized plasma (n
—2
5
10
S-100 protein
0
<0.02
<0.02
0.03
0.046
= 11)
0.063
0.068
0.083
0.092
added [μ&\]
1
0.40
0.51
0.62
0.65
0.76
0.75
0.75
0.66
10
4.44
5.11
6.30
6.02
7.97
7.76
8.48
7.30
S-100 protein reference values
The CSF samples of the reference group contained 1.43
± 0.49 μg/l of S-100 protein (mean ± SD). Values ex-
ceeding 2.4 μg/l (mean + 2 SD) were considered ele-
vated. In the serum of healthy subjects 0.026 ± 0.057
Tab. 2 100 μ§/1 of S-100ao, 25 μ§/1 of S-100a and 12,5 μ§/1 of
S-100b diluted in horse serum were measured in the S-100 protein
assay using S-100a: S-100b as l H- l (by vol.) as calibrator. The
percentage of cross reactivity was calculated.
S-100 protein
subtype
S-100ao
S-100a
S-100b
Concentration
expected
100
25
12.5
detected
0.89
2.91
21.3
Cross-
reactivity
0.90
12
170
Tab. 3 Four different CSF samples were mixed, measured in the
S-100 protein assay and the analytical recovery was calculated as
a percentage. The S-100 protein concentration of the samples was
20.0 μg/l for specimen 1, 0.62 μg/l for specimen 2, 4.00 μg/l for
specimen 3 and 8.20 μg/l for specimen 4.
Combination
of specimens
1 +2
1 +3
1 +4
2 + 3
2 + 4
3 + 4
Concentration
expected
[Mg/1]
10.3
12.0
14.1
2.31
4.41
6.10
detected
ing/i]
10.1
12.0
13.3
2.25
4.40
6.30
Recovery
98
100
94
97
100
103
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of S-100 protein was foundr(mean ± SD). Concen- calibration range. In contrast, 22 of the 30 heparinized
trations in heparinized plasma (0.098 ±0.11 Mg/l, mean plasma samples were within the calibration range.
± SD) were nearly four times as high as in serum. Only ^m n concentrations in blood and CSF were
6 of the 30 serum reference samples were within the
 measured during the dinical course> in neurosurgical pa-
tients. To illustrate the possible diagnostic value of the
method described here one individual course of a patient
suffering from subarachnoid haemorrhage is presented
in figure 4.
100η
8
ώ
l
10 -
1 -
0.1 -
0.01
1:1 1:2 1:4 1:8 1:16 1:32 1:64 1:128
Dilution of CSF samples
Fig. 2 Serial dilution of four CSF samples in horse serum.
100 -ι
οο
ώ
10 -
1 -
0.1
1:1 1:2 1:4 1:8 1:16 1:32
Dilution of blood samples
Fig. 3 S-l 00 protein was added to serum and heparinized plasma
of 12 healthy subjects to give a concentration of 10 μ§/1. Shown
are the mean values of measured S-l00 protein for serum (O) and
heparinized plasma (x) after serial dilution in horse serum.
Tab. 4 Measured concentrations of S-l00 protein after addition
of 1 and 10 μg of S-l00 protein to serum and heparinized plasma
of 30 healthy subjects. In both incubation steps calcium was added
to give a concentration of 5 mmol/1.
Recovery after addition of S-l00 protein
1 μg/l added 10 μg/l added
Serum
(n = 30)
Mean ± SD
Heparinized plasma'
(n = 30)
Mean ± SD
0.669 ±0.47 7.20 ± 1.43
0.775 ± 0.142 9.56 ± 1.58
Discussion
Several groups have reported increased cerebrospinal
fluid levels of S-l00 protein in patients with lesions of
the central nervous system (7-13). There is evidence
that CSF levels of S-l00 protein and other proteins (glial
fibrillary acidic protein, neuron-specific enolase) may
serve as quantitative markers of the extent of brain dam-
age (12, 15, 17-20).
In 1987 Persson et al. (9) reported the determination of
S-l00 protein in CSF and serum, using a radioimmuno-
assay with rabbit and bovine S-l00 protein antibody
from DAKO. In the serum of 16 healthy controls they
found S-l00 protein levels of ^  5.3 μg/L In the clinical
course of one patient with cerebral infarction they also
determined three serum S-l00 protein levels within the
first 48 hours after onset of symptoms. In this particular
case, an increase of S-l00 protein levels in blood was
demonstrated for the first time. Other reports on S-l00
1
8
r 1000
10
£Ο
8ώ
6 10 15 20 25 30 35 40 45
Time after onset of symptoms [d]
Fig. 4 Plasma (D) and CSF (Δ) S-100 protein concentration
course from a 42-year old female with a severe subarachnoid
haemorrhage with hydrocephalus from a ruptured aneurysm of the
anterior communicating artery. Admitted in coma with signs of a
tegmental syndrome.
0 Ventricular cannulation.
(2) Clipping of the aneurysm.
® Due to prolonged brain oedema general anaesthesia with barbi-
turate (methohexital) was performed until day 21 after the opera-
tion.
© Patient breathed spontaneously. The neurological state im-
proved slowly.
© Bacterial meningitis.
© Transfer to a rehabilitation unit. At this time she was able to
communicate, still suffering from a psychosyndrome.
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protein blood levels in patients with brain damage could
not be found in the literature.
The method described measures S-100 protein levels in
blood and CSF with adequate sensitivity and reliability.
The reference range found for CSF (< 2.4 g/l) corre-
sponds well with the values reported in the literature
(7, 13, 21). Several factors may contribute to the clear
differences between the reference values for blood re-
ported by Persson et al. (9) and those reported in the
present study. Persson did not describe the calibrator he
used. The lower detection limit of their method is 1 g/l,
compared with 0.02 g/l in our assay. Therefore, the
main reason may be differences in the calibration. As
long as no international standardisation of S-100 protein
quantification exists, the comparability of absolute val-
ues must remain questionable.
For ethical reasons it is not possible to obtain CSF from
healthy volunteers to establish a reference range for nor-
mal individuals. Instead we selected patients undergoing
myelography for lumbar pain. Neurological examination
and medical history revealed no evidence of an organic
disease of the central nervous system. Nevertheless this
selection remains a compromise. For ethical reasons we
also did not obtain ventricular and lumbar CSF simulta-
neously. Thus we cannot give data concerning the com-
parability of the two sources. However, Aurell et al. (4)
obtained 50 ml of lumbar CSF from patients with nor-
mal pressure hydrocephalus in consecutive portions of
10ml and found no differences in the S-100 protein
levels between the five portions.
The effect of calcium on the measurement of S-100 pro-
tein has already been described by Sindic et al. (13). We
found the same optimal calcium concentration as Sindic
et al., and the addition of 5 mmol/1 CaCl2 decreased the
lower detection limit of our assay. Possible explanations
of the incomplete recovery of S-100 protein from blood
are S-100 protein binding proteins, S-100 protein digest-
ing enzymes or poor affinity of the anitbody used. The
latter, however, appears unlikely since horse serum was
used as diluent for calibrators, controls and all dilutions.
Horse serum was also used to dilute CSF, in order to
minimize matrix effects (22). Horse serum was used in
preference to newborn calf serum, because newborn calf
serum contains high levels of S-100 protein which react
with the antiserum, particularly since this was raised
against bovine S-100 protein. To calculate the analytical
recovery from CSF a classical mixing experiment was
performed. The problem of measuring S-100 protein in
blood is the poor recovery rate, which may be the reason
why reports on S-100 protein measurements in blood are
so rare in the literature. Therefore, we also performed a
recovery experiment in which fixed amounts of S-100
protein were added to the serum and heparinized plasma
of 30 normal individuals.
Whether decreasing calcium levels during blood coagu-
lation are the only reason for the different recoveries in
serum and plasma remains unclear. It is, however, well
known from the literature that calcium induces a confor-
mational change in the S-100 protein molecule and thus
may affect antibody binding (23). In spite of the fact
that calcium is clearly more effective in improving the
recovery of S-100 protein from serum, the absolute re-
covery rates from heparinized plasma remain higher.
This may be caused by unknown factors in serum.
Recovery experiments in EDTA and citrate plasma failed,
because the addition of calcium induced coagulation. The
recovery observed in the experiments to optimize calcium
concentration was lower than that obtained later when
5 mmol/1 CaCl2 was added to all assay buffers.
To assess the clinical importance of the different S-100
protein subtypes (a, b, ao) specific assays must be devel-
oped. Our assay predominantly detected S-100b. With
reference to the distribution of S-100 protein subtypes
described above, this assay appears to be suitable for
studying central nervous system disease.
These preliminary results of S-100 protein measure-
ments in neurosurgical patients may indicate a positive
correlation between S-100 protein plasma levels and
clinical course. In the clinical data shown in figure 4 the
course of S-100 protein levels in blood and CSF appears
to be similar; the slight differences in blood and CSF
may be due to the time-delay caused by the blood-
brain barrier.
In patients with severe polytrauma, S-100ao from outside
the CNS can influence the results of S-100 protein mea-
surements (24, 25). Despite the fact that S-100ao is only
detected to less than 1% with our method, an influence
on the results obtained with this assay cannot be com-
pletely excluded, although it is unlikely to influence the
clinical value of the results.
The assay described above allows a rapid, reliable and
non radioisotopic measurement of S-100 protein in
blood and CSF. Determination of S-100 protein levels
in blood may serve as a useful tool for screening and
monitoring patients suffering from lesions of the central
nervous system. Assessment of the clinical value of this
method will require prospective studies with large pa-
tient populations.
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